Taylor Martin S, Hwang Yousang, Hsiao Po-Yuan, Boeke Jef D, Cole Philip A
Department of Pharmacology & Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Methods Enzymol. 2012;514:205-28. doi: 10.1016/B978-0-12-381272-8.00013-1.
Ghrelin O-acyltransferase (GOAT) is responsible for catalyzing the attachment of the eight-carbon fatty acid octanoyl to the Ser3 side chain of the peptide ghrelin to generate the active form of this metabolic hormone. As such, GOAT is viewed as a potential therapeutic target for the treatment of obesity and diabetes mellitus. Here, we review recent progress in the development of cell and in vitro assays to measure GOAT action and the identification of several synthetic GOAT inhibitors. In particular, we discuss the design, synthesis, and characterization of the bisubstrate analog GO-CoA-Tat and its ability to modulate weight and blood glucose in mice. We also highlight current challenges and future research directions in our biomedical understanding of this fascinating ghrelin processing enzyme.
胃饥饿素O-酰基转移酶(GOAT)负责催化八碳脂肪酸辛酰基连接到肽类胃饥饿素的Ser3侧链上,以生成这种代谢激素的活性形式。因此,GOAT被视为治疗肥胖症和糖尿病的潜在治疗靶点。在此,我们综述了用于测量GOAT活性的细胞和体外测定方法的最新进展,以及几种合成GOAT抑制剂的鉴定。特别是,我们讨论了双底物类似物GO-CoA-Tat的设计、合成和表征及其调节小鼠体重和血糖的能力。我们还强调了在对这种迷人的胃饥饿素加工酶的生物医学理解方面当前面临的挑战和未来的研究方向。